Marianne van Fessem
Overview
Explore the profile of Marianne van Fessem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lane K, Dixon J, McKeown D, Johnston A, van Schaik R, van Fessem M, et al.
Intensive Care Med
. 2014 Jun;
40(8):1177-8.
PMID: 24968714
No abstract available.
2.
van Schaik R, Kok M, Sweep F, van Vliet M, van Fessem M, Meijer-Van Gelder M, et al.
Pharmacogenomics
. 2011 Aug;
12(8):1137-46.
PMID: 21830868
Aims: Tamoxifen is metabolized by cytochrome P450s, with an important role for CYP2D6. Recently, we demonstrated in 80 patients that CYP2C19*2 is associated with increased survival in breast cancer patients...
3.
Allegaert K, van Schaik R, Vermeersch S, Verbesselt R, Cossey V, Vanhole C, et al.
Pediatr Res
. 2008 Mar;
63(6):674-9.
PMID: 18317231
To document determinants of O-demethylation in critically ill (pre)term neonates and infants, tramadol (M) and O-demethyl tramadol (M1) concentrations were quantified in eighty-six 24 h urine collections and 168 plasma...
4.
Chai W, Hoedemaekers Y, van Schaik R, van Fessem M, Garrelds I, Saris J, et al.
J Renin Angiotensin Aldosterone Syst
. 2007 Feb;
7(4):225-30.
PMID: 17318792
Left ventricular (LV) hypertrophy in subjects with hypertrophic cardiomyopathy (HCM) is variable, suggesting a role for modifying factors. Here, we determined whether aldosterone modulates hypertrophy in HCM. Cardiac and/or plasma...